A report released on this week by the Pharmaceutical Research and Manufacturers of America (PhRMA), “Researching Cancer Medicines: Setbacks and Stepping Stones,”
A report released on this week by the Pharmaceutical Research and Manufacturers of America (PhRMA), “
Researching Cancer Medicines: Setbacks and Stepping Stones,” highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called “failures” are a crucial part of the drug development process.
The report illustrates the immense challenges in bringing new medicines to patients with cancer and explores the factors that contributed to both the approvals of new treatments and those that “failed” between 1998 and 2014. The report focuses on three cancers that are particularly difficult to treat: melanoma, lung cancer, and brain cancer.
The report found that 96 potential treatments for melanoma did not make it through clinical trials, but paved the way for seven approved medicines, a nearly 14:1 ratio of failures to successes. Ten medicines have been approved to treat lung cancer, whereas 167 potential treatments did not make it through clinical trials. Only three new medicines have been approved to treat brain cancer, while 75 investigational medicines were unsuccessful in the development process.
Despite these challenges, America’s biopharmaceutical companies continue to invest in research to develop new treatments. According to a new report by PhRMA, there are 771 cancer medicines and vaccines either in clinical trials or awaiting review by FDA. Of these medicines, more than 50 are for the treatment of melanoma, 98 for lung cancer, and 47 for brain cancer.
“While it may sound counterintuitive, research setbacks are instrumental to furthering efforts to better understand a disease and how to treat it. They are also an indication of the incredible difficulty in developing medicines to treat cancer,” said PhRMA President and CEO John J. Castellani in a press release.
Source: PhRMA
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.